

## Disclosures

### Personal Commercial (16)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
<b>Self</b>			
AstraZeneca Pharmaceuticals	Research/Research Grants ‡ DAPA ACT HF-TIMI 68	None (\$0)	Heart Failure and Cardiomyopathies
AstraZeneca Pharmaceuticals	Consultant Fees/Honoraria	Significant (>= \$5,000)	General Cardiology
Beckman Coulter	Other - Participation on clinical endpoint committee	Modest (< \$5,000)	General Cardiology
CeleCor Therapeutics	Other - Participation on clinical endpoint committee	Significant (>= \$5,000)	Acute Coronary Syndromes
Kowa Pharmaceuticals	Other - Participation on clinical endpoint committee	Significant (>= \$5,000)	Stable Ischemic Heart Disease
Merck & Co., Inc.	Research/Research Grants ‡ CORALreef Outcomes	None (\$0)	Stable Ischemic Heart Disease
Metabolic Endocrine Education Foundation	Speaker's Bureau	Modest (< \$5,000)	General Cardiology
Novo Nordisk Inc.	Other - Participation on clinical endpoint committee	Significant (>= \$5,000)	General Cardiology
Pfizer Inc	Consultant Fees/Honoraria	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
Pfizer Inc	Research/Research Grants ‡ GARDEN-TIMI 74	None (\$0)	Heart Failure and Cardiomyopathies
Pri-Med	Consultant Fees/Honoraria	Modest (< \$5,000)	Acute Coronary Syndromes
Radcliffe Cardiology	Consultant Fees/Honoraria	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
Tosoh Biosciences	Other - Participation on clinical endpoint committee	Significant (>= \$5,000)	General Cardiology
Translational Medicine Academy	Consultant Fees/Honoraria	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
USV Private Limited	Consultant Fees/Honoraria	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
Youngene Therapeutics	Consultant Fees/Honoraria	Modest (< \$5,000)	Heart Failure and Cardiomyopathies

### Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

### Personal Organizational or Other Non-Commercial (0)

No disclosures on record

### Clinical Trial Enroller (0)

No disclosures on record

### Institutional Financial Decision-Making Role (0)

No disclosures on record

### Expert Witness Testimony (0)

No disclosures on record

† Commercial Funding Source | ‡ Trial Name

## Agreement

**Certified Education Attestation** | Signed on 12/15/2025

URL for full agreement: <http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement>

**Confidentiality, Disclosure and Assignment Agreement** | Signed on 12/15/2025

**Embargo** | Signed on 12/15/2025

*URL for full agreement: <http://disclosures.acc.org/Public/Definition/EmbargoAgreement>*

**On-Going Obligation Agreement** | Signed on 12/15/2025

---

### **ACC and Disclosures**

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.